Vertex Pharmaceuticals (VRTX) Capital Expenditures (2009 - 2026)

Vertex Pharmaceuticals has reported Capital Expenditures for 18 years, with the latest figure at $133.4 million in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures rose 227.76% year-over-year to $133.4 million; the trailing twelve-month figure through Mar 2026 stood at $530.3 million (up 96.41% YoY), and the FY2025 full-year result was $437.6 million, up 46.99% from the prior year.
• Capital Expenditures for Q1 2026 stood at $133.4 million, down from $149.4 million in the prior quarter.
• The five-year high for Capital Expenditures was $149.4 million in Q4 2025, with the low at $33.6 million in Q4 2022.
• Average Capital Expenditures over 5 years is $74.9 million, with a median of $63.6 million recorded in 2022.
• Year-over-year, Capital Expenditures slumped 45.63% in 2022 and surged 227.76% in 2026.
• Tracing VRTX's Capital Expenditures over 5 years: stood at $33.6 million in 2022, then surged by 72.92% to $58.1 million in 2023, then soared by 59.38% to $92.6 million in 2024, then soared by 61.34% to $149.4 million in 2025, then slipped by 10.71% to $133.4 million in 2026.
• The last three Capital Expenditures figures came in at $133.4 million (Q1 2026), $149.4 million (Q4 2025), and $101.8 million (Q3 2025), per Business Quant data.

Peer Comparison